Showing results (151-160 of 233) with videos related to

Sort By:
Pageof 24
HGG Advances|February 22, 2025
Male proband with intractable seizures and a de novo start-codon-disrupting variant in GLULElizabeth Carbonell, Sarah L Stenton, Vijay S Ganesh, et al.
BMC Cancer|November 14, 2019
Advanced neoplasia in Veterans at screening colonoscopy using the National Cancer Institute Risk Assessment ToolLaura W Musselwhite, Thomas S Redding, Kellie J Sims, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 1, 1990
Total body irradiation and bone marrow transplantation for immunodeficiency disorders in young childrenF E Halberg, W M Wara, K E Weaver, et al.
Anesthesiology|August 1, 1997
A comparison of remifentanil and morphine sulfate for acute postoperative analgesia after total intravenous anesthesia with remifentanil and propofolJ Yarmush, R D'Angelo, B Kirkhart, et al.
Preventive Medicine|November 1, 2019
Estimating the impact of insurance expansion on colorectal cancer and related costs in North Carolina: A population-level simulation analysisKristen Hassmiller Lich, Meghan C O'Leary, Siddhartha Nambiar, et al.
Prehospital Emergency Care|July 7, 2020
Inferior Vena Cava Diameter is an Early Marker of Central Hypovolemia during Simulated Blood LossBlair D Johnson, Zachary J Schlader, Michael W Schaake, et al.
Preventive Medicine|October 23, 2019
Mailed FIT (fecal immunochemical test), navigation or patient reminders? Using microsimulation to inform selection of interventions to increase colorectal cancer screening in Medicaid enrolleesMelinda M Davis, Siddhartha Nambiar, Maria E Mayorga, et al.
Pediatrics|October 22, 2021
An Intervention to Improve Chlamydia and Gonorrhea Testing Among Adolescents in Primary CareMargaret M Tomcho, Yingbo Lou, Sonja C O'Leary, et al.
Public Health|September 9, 2023
COVID-19 vaccine safety in Scotland - background rates of adverse events of special interestL A Cullen, Z Grange, K Antal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2018
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic LeukemiaMaura C O'Leary, Xiaobin Lu, Ying Huang, et al.
Pageof 24